| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/26/2010 | US7652060 Small molecule rotamase enzyme inhibitors |
| 01/26/2010 | US7652054 Gastrointestinal disorders; cardiovascular disorders; dyspepsia;anticancer agents; antiulcer agents |
| 01/26/2010 | US7652045 Activator of peroxisome proliferator-activated receptor δ |
| 01/26/2010 | US7652035 CRF receptor antagonists and methods relating thereto |
| 01/26/2010 | US7652022 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; |
| 01/26/2010 | US7652017 Therapy for central nervous system, brain disorders |
| 01/26/2010 | US7652012 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof |
| 01/26/2010 | US7652011 Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine |
| 01/26/2010 | US7652006 Substituted 1(2H)-phthalazinones and pharmaceutical compositions thereof |
| 01/26/2010 | US7651703 Comprising hyaluronic acid or sodium hyaluronate dissolved in physiological buffer at concentration of 0.01-3 percent weight per volume and particles comprising first component biologically active agent and second component biocompatible polymeric matrix; use of 23-gauge or smaller bore needle |
| 01/26/2010 | US7651698 Prolonged release bioadhesive therapeutic systems |
| 01/26/2010 | CA2532437C N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto |
| 01/26/2010 | CA2481012C Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 01/26/2010 | CA2470064C Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 01/26/2010 | CA2468748C Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 01/26/2010 | CA2456606C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 01/26/2010 | CA2447099C Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/26/2010 | CA2434731C Modular infusion device and method |
| 01/26/2010 | CA2422889C Method for the treatment of neurological and neuropsychological disorders |
| 01/26/2010 | CA2404237C Methods of investigating, diagnosing, and treating amyloidosis |
| 01/26/2010 | CA2394188C Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/26/2010 | CA2393083C Use of hypoglycemic agent for treating impaired glucose metabolism |
| 01/26/2010 | CA2390263C Method for producing metabolites from plants cultivated in soil-less medium |
| 01/26/2010 | CA2390029C Suspension comprising oxcarbazepine |
| 01/26/2010 | CA2346084C Benzothieno[3,2-c]pyridines as .alpha.2 antagonists |
| 01/26/2010 | CA2219406C Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 01/26/2010 | CA2213567C Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor |
| 01/26/2010 | CA2201841C Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| 01/21/2010 | WO2010009290A1 Alpha7 nicotinic acetylcholine receptor inhibitors |
| 01/21/2010 | WO2010009183A1 Pyridone and pyridazone analogues as gpr119 modulators |
| 01/21/2010 | WO2010009139A2 Imidazolyl pyrimidine inhibitor compounds |
| 01/21/2010 | WO2010009120A2 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| 01/21/2010 | WO2010009062A1 Imidazole carboxamides |
| 01/21/2010 | WO2010008843A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 01/21/2010 | WO2010008832A1 Pyrrolo-pyridine-3-yl-piperazine derivatives having 5-ht6 receptor affinity |
| 01/21/2010 | WO2010008776A2 Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems |
| 01/21/2010 | WO2010008775A1 Aminopyridopyrazinone derivatives for treating neurodegenerative diseases |
| 01/21/2010 | WO2010008735A2 Solid states of o-desmethylvenlaf axine salts |
| 01/21/2010 | WO2010008619A2 Extended release pharmaceutical formulations of s-adenosylmethionine |
| 01/21/2010 | WO2010008528A2 Marek's disease virus vaccine compositions and methods of using thereof |
| 01/21/2010 | WO2010008513A2 Devices for the treatment of vascular aneurysm |
| 01/21/2010 | WO2010008005A1 Agent for ameliorating immune system function abnormality induced by stress |
| 01/21/2010 | WO2010007972A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 01/21/2010 | WO2010007966A1 Azole compound |
| 01/21/2010 | WO2010007788A1 Glycyrrhetinic acid derivative and use thereof |
| 01/21/2010 | WO2010007382A1 Benzazepine derivatives and their use as hstamine h3 antagonists |
| 01/21/2010 | WO2010007318A2 Novel imidazo[1,2-a]pyrimidine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| 01/21/2010 | WO2010007316A2 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 01/21/2010 | WO2010007181A2 New salt forms of an aminoindan derivative |
| 01/21/2010 | WO2010007179A1 Heterocyclic derivatives that are used in the treatment of neurodegenerative diseases |
| 01/21/2010 | WO2010007074A1 Pyrazolo [1, 5-a] pyrimidine derivatives |
| 01/21/2010 | WO2010007073A1 Piperazine derivatives used as cav2.2 calcium channel modulators |
| 01/21/2010 | WO2010007072A1 Piperazine derivatives used as cav2.2 calcium channel modulators |
| 01/21/2010 | WO2010007032A1 Piperidine based ureas as nk1 antagonists |
| 01/21/2010 | WO2010006772A2 Use of cd95 inhibitors for the treatment of inflammatory disorders |
| 01/21/2010 | WO2010006704A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 01/21/2010 | WO2009134383A3 Vinyl substituted fatty acids |
| 01/21/2010 | WO2009120192A3 Processes for the preparation of benzo-fused dioxin derivatives |
| 01/21/2010 | WO2009117127A3 Nerve repair with a hydrogel and optional adhesive |
| 01/21/2010 | WO2009103319A3 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases |
| 01/21/2010 | WO2007041130A3 Deazapurines useful as inhibitors of janus kinases |
| 01/21/2010 | US20100016783 Non-invasive systems and methods for in-situ photobiomodulation |
| 01/21/2010 | US20100016600 N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith |
| 01/21/2010 | US20100016579 Crystalline forms of quetiapine hemifumarate |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016444 Methods and Compositions for Treating Mammalian Nerve Tissue Injuries |
| 01/21/2010 | US20100016442 Small molecule solubilization system |
| 01/21/2010 | US20100016437 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| 01/21/2010 | US20100016433 Nerve-regenerating agent |
| 01/21/2010 | US20100016409 Rna Nanoparticles and Nanotubes |
| 01/21/2010 | US20100016403 Use of d-serine derivatives for the treatment of anxiety disorders |
| 01/21/2010 | US20100016402 Unit dose formulations of ketorolac for intranasal administration |
| 01/21/2010 | US20100016401 3-aza-bicyclo[3.1.0]hexane derivatives |
| 01/21/2010 | US20100016399 GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders |
| 01/21/2010 | US20100016397 Pyrrole and Pyrazole DAAO Inhibitors |
| 01/21/2010 | US20100016391 Isoxazoline Compounds Having MIF Antagonist Activity |
| 01/21/2010 | US20100016386 Selective glycosidase inhibitors and uses thereof |
| 01/21/2010 | US20100016377 Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders |
| 01/21/2010 | US20100016371 Indole Compounds |
| 01/21/2010 | US20100016363 Fixed Combination Dosage Forms for the Treatment of Migraine |
| 01/21/2010 | US20100016360 Alpha7 nicotinic acetylcholine receptor inhibitors |
| 01/21/2010 | US20100016344 Amino heterocyclic linked pyrimidine derivatives |
| 01/21/2010 | US20100016343 Alpha7 nicotinic acetylcholine receptor inhibitors |
| 01/21/2010 | US20100016332 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 01/21/2010 | US20100016321 Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulator |
| 01/21/2010 | US20100016312 Substituted indolyl and indazolyl derivatives and uses thereof |
| 01/21/2010 | US20100016309 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same |
| 01/21/2010 | US20100016303 Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
| 01/21/2010 | US20100016297 Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| 01/21/2010 | US20100016290 Amorphous polymorph of bazedoxifene acetate |
| 01/21/2010 | US20100016288 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| 01/21/2010 | US20100016287 Compounds having affinity for dopamine d3 receptor and uses thereof" |
| 01/21/2010 | US20100016284 Compounds and uses thereof - 151 |
| 01/21/2010 | US20100016283 Compounds and uses thereof - 150 |
| 01/21/2010 | US20100016281 Pyrimidine compounds as serotonin receptor modulators |
| 01/21/2010 | US20100016280 Low Dosage Serotonin 5-HT2A Receptor Agonist To Suppress Inflammation |
| 01/21/2010 | US20100016278 Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| 01/21/2010 | US20100016277 Diazabicyclic central nervous system active agents |
| 01/21/2010 | US20100016272 Heteroarylacrylamides and their use as pharmaceuticals |
| 01/21/2010 | US20100016250 Toll-like receptor 9 agonists |